14 commercial payer policies list J9061. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
14 policies from 12 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J9061 |
|---|---|---|
| Amivantamab-vmjw (Rybrevant) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Amivantamab-vmjw (Rybrevant) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) | Not recorded | Covered with conditionsInferred from policy title |
| Policy | Effective | Status of J9061 |
|---|---|---|
| Amivantamab-vmjw (Rybrevant) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Amivantamab-vmjw (Rybrevant) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9061 |
|---|---|---|
| Amivantamab-vmjw (e.g., Rybrevant) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9061 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9061 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9061 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9061 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9061 |
|---|---|---|
| Amivantamab-vmjw (Rybrevant) | Aug 31, 2021 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9061 |
|---|---|---|
| Cigna MedOnc Master Drug List.pdf | Not recorded | Prior auth required |
| Policy | Effective | Status of J9061 |
|---|---|---|
| Amivantamab-vmjw (Rybrevant), Amivantamab/Hyaluronidase-lpuj (Rybrevant Faspro); CP.PHAR.544 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9061 |
|---|---|---|
| Q3 - 2026 Jefferson Health Plans MedOnc Master Drug List | Not recorded | Prior auth required |
| Policy | Effective | Status of J9061 |
|---|---|---|
| Rybrevant (amivantamab-vmjw) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |